Insider Transactions in Q1 2022 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+2.83%
|
-
|
|
Jan 21
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,787
+22.69%
|
-
|
|
Jan 21
2022
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
106,244
+7.34%
|
-
|
|
Jan 21
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+31.85%
|
-
|
|
Jan 21
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,021
+9.24%
|
$78,546
$26.73 P/Share
|
|
Jan 14
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.48%
|
$15,000
$40.56 P/Share
|
|
Jan 14
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,400
+4.13%
|
$13,600
$4.31 P/Share
|
|
Jan 14
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.19%
|
$50,000
$40.56 P/Share
|
|
Jan 14
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.18%
|
$2,500
$2.67 P/Share
|
|
Jan 12
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,161
+3.33%
|
$20,644
$4.04 P/Share
|
|
Jan 03
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.53%
|
$17,625
$47.31 P/Share
|
|
Jan 01
2022
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+5.61%
|
-
|
|
Jan 01
2022
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+50.0%
|
-
|
|
Jan 01
2022
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+0.62%
|
-
|
|
Jan 01
2022
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+31.43%
|
-
|
|
Jan 01
2022
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,230
+50.0%
|
-
|